A total of 2011 BC patients ( 18-65 years , pN1 ) were entered into a randomized phase III trial comparing 4 E90C600 q3w followed by 4 docetaxel 100 q3w ( n = 1008 ) with the current standard : 6 F500E100C500 q3w ( n = 828 ) or C600M40F600 d1 , 8 q4w ( n = 175 ) .